Gamma Oryzanol

Plant-derived nanoparticles have demonstrated significant anticancer effects. Researchers recently developed rice bran-derived nanoparticles (rbNPs) that efficiently suppressed cell proliferation and induced programmed cell death of only cancer cells. Furthermore, rbNPs successfully suppressed the growth of tumors in mice having aggressive adenocarcinoma in their peritoneal cavity, without any adverse effects. Given their low production costs and high efficacy, rbNPs hold great promise for developing affordable and safe anticancer agents. Plant-derived nanoparticles have demonstrated significant anticancer effects. Researchers recently developed rice bran-derived nanoparticles (rbNPs) that efficiently suppressed cell proliferation and induced programmed cell death of only cancer cells. Furthermore, rbNPs successfully suppressed the growth of tumors in mice having aggressive adenocarcinoma in their peritoneal cavity, without any adverse effects. Given their low production costs and high efficacy, rbNPs hold great promise for developing affordable and safe anticancer agents. Several types of conventional cancer therapies, such as radiotherapy or chemotherapy, destroy healthy cells along with cancer cells. In advanced stages of cancer, tissue loss from treatments can be substantial and even fatal. Cutting-edge cancer therapies that employ nanoparticles can specifically target cancer cells, sparing healthy tissue. Recent studies have demonstrated that plant-derived nanoparticles (pdNPs) that have therapeutic effects can be an effective alternative to traditional cancer treatments. However, no pdNPs have been approved as anticancer therapeutic agents till date. Rice bran is a byproduct generated during rice refining process that has limited utility and low commercial value. However, it contains several compounds with anticancer properties, such as γ-oryzanol and γ-tocotrienol. To explore these therapeutic properties of rice bran, a team of researchers led by Professor Makiya Nishikawa from Tokyo University of Science (TUS) in Japan developed nanoparticles from rice bran and tested their effectiveness in mice models. Their study, published in Volume 22 of Journal of Nanobiotechnology on 16 March 2024, was co-authored by Dr. Daisuke Sasaki, Ms. Hinako Suzuki, Associate Professor Kosuke Kusamori, and Assistant Professor Shoko Itakura from TUS. "In recent years, an increasing number of new drug modalities are being developed. At the same time, development costs associated with novel therapies have increased dramatically, contributing to the burden of medical expenses. To address this issue, we used rice bran, an industrial waste with anticancer properties, to develop nanoparticles," explains Prof. Nishikawa. The study evaluated the anticancer effects of rice bran-derived nanoparticles (rbNPs), which were obtained by processing and purifying a suspension of Koshihikari rice bran in water. When a cancer cell line named colon26 was treated with rbNPs, cell division was arrested and programmed cell death was induced, indicating strong anticancer effects of the nanoparticles. The observed anticancer activity of rbNPs can be attributed to γ-tocotrienol and γ-oryzanol, that are easily taken up by cancer cells resulting in cell cycle arrest and programmed cell death. Additionally, rbNPs reduced the expression of proteins, such as β-catenin (a protein associated with Wnt signaling pathway involved in cell proliferation) and cyclin D1, which are known to promote cancer recurrence and metastases. Moreover, the rbNPs reduced the expression of β-catenin only in colon26 cells without affecting the non-cancerous cells. "A key concern in the context of pdNPs is their low pharmacological activity compared to pharmaceutical drugs. However, rbNPs exhibited higher anticancer activity than DOXIL®, a liposomal pharmaceutical formulation of doxorubicin. Additionally, doxorubicin is cytotoxic to both cancer cells and non-cancerous cells, whereas rbNPs are specifically cytotoxic to cancer cells, suggesting that rbNPs are safer than doxorubicin," highlights Prof.Nishikawa. To confirm the anticancer properties of rbNPs in the living body, the researchers injected rbNPs into mice having aggressive adenocarcinoma in their peritoneal cavity (enclosed by the diaphragm, abdominal muscles, and pelvis and houses organs like intestines, liver, and kidneys). They observed significant suppression of tumor growth with no adverse effects on the mice. Additionally, the rbNPs significantly inhibited metastatic growth of murine melanoma B16-BL6 cells in a lung metastasis mouse model. Rice bran has several attributes that make it an excellent source of therapeutic pdNPs. Firstly, it is economic as compared to many other sources of pdNPs. Nearly 40% of the rice bran is discarded in Japan, providing a readily available source of raw material. Secondly, the preparation efficiency of rbNPs is higher than that of previously reported pdNPs. Besides being practical and safe as an anticancer therapeutic, the physicochemical properties of rbNPs are very stable. However, a few parameters, such as establishment of separation technologies at the pharmaceutical level, assessing production process control parameters, and evaluation of efficacy and safety in human cancer cell lines and xenograft animal models, must be investigated prior to clinical trials in humans. In conclusion, rice bran, an agricultural waste product, is a source of therapeutic pdNPs that are affordable, effective, and safe, and has the potential to revolutionize cancer treatment in the future. "By establishing a manufacturing method for rice bran nanoparticles with stable quality and confirming their safety and effectiveness, we can develop drugs for cancer treatment that are sustainable, eco-friendly, and affordable. Consequently, we may be able to help more cancer patients maintain good physical and mental health after treatment," concludes Prof. Nishikawa.

数字经济的发展使产业数字化成必然趋势。作为高成效、低成本的获客方式，数字化营销受到了众多企业欢迎，医药行业也纷纷选择加大投入。为促进制药行业数字经济发展，通过线上贸易对接，达成买卖双方合作，2024年，制药在线将携手CPHI & PMEC China推出制药产业线上主题展。主题展贯穿全年，覆盖天然提取物、维生素类、生命科学与生物医药、制粒干燥、玻璃药包、反应设备6大主题，旨在为制药行业带来全年不落幕的展会体验。2024年4月1日至30日，首场制药产业线上主题展正式上线。此次线上展将聚焦天然提取物产业，旨在为350+天然提取物厂家提供供需对接、贸易撮合等服务。同时，线上展期间还将陆续推出药食同源、保健品原料应用等相关主题直播以及对企业高层的采访，共话行业新风向，共谋产业新发展。活动亮点抢先看01主题直播/企业专访探讨前沿技术，对话企业高层📌时间：4月1日 14:00-15:30天然提取物空中学苑—药食同源专场讲师：朱秀敏 邢台学院生物科学与工程学院教授；营养与食品安全研究中心主任於洪建 天津科技大学新农村发展研究院副院长；合肥和晨生物总经理📌时间：4月10日企业专访演讲人：王婷婷部长  大连医诺生物股份有限公司 品牌与市场部📌时间：4月15日 14:00-14:45天然食品资源高值化利用的技术创新与实践讲师：张连富  江南大学食品学院教授，工学博士，博士生导师🎉🎉🎉更多采访敬请期待🔍二维码预约观看02线上展厅350+源头工厂，8000+优质产品部分推荐厂家及产品盘锦天源药业有限公司公司是2004年新建的符合GMP要求的，以水飞蓟提取物为主导产品的国家高新技术企业。主要产品为水飞蓟系列产品：水飞蓟素（丙酮提取、乙酸乙酯提取、乙醇提取）、水溶性水飞蓟素、水飞蓟宾、水飞蓟籽油、保健食品水飞蓟胶囊、蓟葛五灵颗粒以及外用制剂等。主营产品：水飞蓟素、水飞蓟提取物、水飞蓟宾…浙江得乐康食品股份有限公司得乐康成立于1994年，在米糠、银杏叶、茶叶这三种原料的开发和利用上精益求精，分别推出谷维素、阿魏酸、米糠油、植物甾醇、糠甾醇；银杏叶提取物、莽草酸、奎宁酸、银杏内酯；绿茶提取物、茶氨酸、茶黄素、EGCG、EC、ECG、EGC等产品。不断追求品质提升，同时降低生产成本，为客户提供高性价比产品是我们的追求和骄傲。主营产品：银杏叶提取物、绿茶提取物、天然茶氨酸、EGCG、谷维素、阿魏酸、莽草酸、奎宁酸、米糠油…吉林省宏久生物科技股份有限公司吉林省宏久生物科技股份有限公司于1998年创建于中国长白山脚下，是一家专业从事天然产品种植、研发、生产与销售的民营股份制高新技术企业。其天然植物提取物产品广泛应用于全球功能性食品饮料、保健品、化妆品、膳食补充剂和制药等领域。主营产品：人参茎叶总皂苷、红参浸膏、人参浸膏、西洋参提取物、人参提取物…杭州双马生物科技股份有限公司双马生物是一家以食品、医药原料中间体、医药保健品等的研发、生产及销售为核心业务的高新技术企业。公司生产销售的红曲、功能性红曲（粉）、红曲胶囊系列保健品，畅销全国二十多个省市，远销美国、欧洲、东南亚及南美等国家和地区。公司作为国内较早从事功能性红曲研发生产的企业之一，在该领域拥有高知名度和影响力。主营产品：红曲粉、功能性红曲粉、红曲米…陕西华晨生物科技有限公司陕西华晨生物科技有限公司是一家专注于植物、动物提取物的研究、生产及销售的高科技企业。公司在杨凌设立工厂，年处理原材料 800吨 ，并先后取得了SC、ISO22000、HALAL等认证，公司自成立以来，始终坚持以人才为本、诚信立业的经营原则，荟萃业界精英，将先进的生产技术、管理方法及企业经验与本公司的具体实际相结合，始终为客户提供好的产品和技术支持以及健全的售后服务。使企业在激烈的市场竞争中始终保持竞争力，实现公司快速、稳定地发展。公司主打产品有：富里酸，芦丁，锯叶棕提取物，番泻叶提取物，紫草提取物。主营产品：喜来芝提取物，黑姜提取物，东革阿里…惠州市康维健生物科技有限公司惠州市康维健生物科技有限公司位于广东省惠州市三和经济开发区，致力于为全球食品、化妆品原料 、保健食品原料、药用辅料、动物营养提供安全、优质的产品和服务。公司是一家具有生物合成技术的国家高新技术企业，拥有自主研发的酯类酶法合成工艺技术平台（拥有专利16项，技术秘密100余项），实现了抗坏血酸棕榈酸酯的环保生产，工厂产能3300吨/年。基于酯类酶法合成工艺技术，还有多款产品可进行商业化生产。包括酶法生产植物甾醇酯、抗坏血酸硬脂酸酯、维生素A棕榈酸酯、抗坏血酸油酸酯、抗坏血酸亚油酸酯、抗坏血酸亚麻。主营产品：抗坏血酸棕榈酸酯、抗坏血酸硬脂酸酯、抗坏血酸…湖南禹健生物科技有限公司湖南禹健生物科技有限公司是一家以纯天然植物提取物为主，适用于健康食品，膳食补充，食品饮料，保健品复方等专业领域的高科技创新型企业。公司集研发、生产、销售于一体，主要产品有速溶玫瑰花提取物，速溶茶提取物及名贵菌类提取物等。公司严格按照GMP操作标准生产管理，已取得Organic Kosher，Halal，IS09001等一系列国内外的品质证书及管理资质。主营产品：灵芝提取物，蝶豆花提取物，速溶玫瑰花提取物…🔍下方二维码浏览更多产品及厂家信息03热门活动活动时间: 2024年4月1-30日《天然提取物精选厂家名录》免费下载参与方式：STEP1-登陆/注册制药在线买家会员账号STEP2-点击下载发询盘享CPHI & PMEC China VIP观众权益惊喜福利：1. 自主询盘3个，定制咖啡杯1个2. 自主询盘3个以上，小米双肩包1个扫描下方二维码参与活动活动咨询活动联系：李女士 021-33392269买家客服：姚女士 021-3339225404线下展联动CPHI China 2024 天然提取物线下展🔍6月14日前完成观众登记，省100元现场门票费！2024年6月19-21日，由Informa Markets、中国医药保健品进出口商会主办，上海博华国际展览有限公司协办的“第二十二届世界制药原料中国展”将在上海浦东新国际博览中心盛大召开。“天然提取物展区”作为CPHI China的特色展区之一，将在展示新产品、新思路、新技术的同时，持续关注政策最新动向、聚焦市场发展趋势，助力企业打开产品创新路径，推动天然提取物上下游产业共同实现转型升级。还等什么立即扫码参与活动吧！活动咨询活动联系：李女士 021-33392269买家客服：姚女士 021-33392254👇👇点击“阅读原文”限时免费领取参观门票！